<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="108434">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01692691</url>
  </required_header>
  <id_info>
    <org_study_id>12-10</org_study_id>
    <nct_id>NCT01692691</nct_id>
  </id_info>
  <brief_title>Dacarbazine and Carmustine in Metastatic Melanoma</brief_title>
  <official_title>Phase II Trial of Sequenced Chemotherapy With Dacarbazine and Carmustine With NeulastaÂ® Support in Previously Treated Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Regional Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether dacarbazine and carmustine at the doses
      and schedule used in this study will help to increase tumor shrinkage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase II trial, patients with stage IV melanoma will be treated with dacarbazine and
      carmustine commonly used in this cancer, but given using a schedule that might theoretically
      improve on this combination. Patients on this study will be assessed in terms of toxicity,
      response rate, median duration of response, median time to disease progression, and median
      survival.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival of Patients With Stage IV Melanoma Who Have Had Disease Progression on at Least One Prior Systemic Therapy</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Duration of Response</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Survival of Patients Treated With Combination.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Melanoma Metastatic</condition>
  <arm_group>
    <arm_group_label>Dacarbazine, carmustine, neulasta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dacarbazine IV - Day 1; Carmustine IV - Day 2; Neulasta SC - Day 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>Dacarbazine IV - Day 1</description>
    <arm_group_label>Dacarbazine, carmustine, neulasta</arm_group_label>
    <other_name>DTIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Carmustine IV- Day 2</description>
    <arm_group_label>Dacarbazine, carmustine, neulasta</arm_group_label>
    <other_name>BCNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neulasta</intervention_name>
    <description>Neulasta SC - Day 3</description>
    <arm_group_label>Dacarbazine, carmustine, neulasta</arm_group_label>
    <other_name>pegfilgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have a histologically-proven diagnosis of metastatic malignant melanoma
             which has progressed on at least one prior systemic therapy.

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 and
             estimated survival of at least 3 months.

          3. Patients must be felt to have recovered from effects of prior cancer therapy, such as
             past expected leukocyte nadir for chemotherapy (&gt; 2 weeks).

          4. Absolute granulocyte count of at least 1500/mm3; hemoglobin of at least 9 gm/dl;
             platelet count of at least 100,000/mm3; bilirubin must be less than 1.5 mg/dl; ALT
             and AST must be less than 3 times the upper limit of normal; creatinine must be less
             than or equal to 1.8 mg/dl.

          5. Women of childbearing potential must have a negative pregnancy test and adequate
             precautions to prevent pregnancy during treatment must be taken.

          6. Patient consent must be obtained prior to entrance onto study.

          7. Patients must have no evidence of significant cardiovascular disease including
             history of recent (&lt; 6 months) myocardial infarction, uncompensated congestive heart
             failure, uncontrolled angina or cerebrovascular accident.

        Exclusion Criteria:

          1. Evidence of significant cardiovascular disease including history of recent (&lt; 6
             months) myocardial infarction, uncompensated congestive heart failure, uncontrolled
             angina, or cerebrovascular accident.

          2. Prior history of psychiatric disorder that could be exacerbated by or which could
             preclude completion of this therapy.

          3. Pregnancy or lactation.

          4. Prior chemotherapy with carmustine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Quan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Regional Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Regional Medical Center</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 2, 2016</lastchanged_date>
  <firstreceived_date>August 29, 2012</firstreceived_date>
  <firstreceived_results_date>January 1, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western Regional Medical Center</investigator_affiliation>
    <investigator_full_name>Walter Quan Jr., MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Melanoma Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dacarbazine Carmustine</title>
          <description>All patients received chemotherapy with Dacarbazine and Carmustine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Number of Participants</title>
          <description>Dacarbazine Carmustine</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival of Patients With Stage IV Melanoma Who Have Had Disease Progression on at Least One Prior Systemic Therapy</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progression Free Survival at 8 Weeks</title>
            <description>Dacarbazine + Carmustine</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival of Patients With Stage IV Melanoma Who Have Had Disease Progression on at Least One Prior Systemic Therapy</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Response Rate</title>
            <description>Dacarbazine Carmustine</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Duration of Response</title>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Survival of Patients Treated With Combination.</title>
        <time_frame>8 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Number of Participants</title>
          <description>Dacarbazine Carmustine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>gastroesophageal reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Arthalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heather Barilla</name_or_title>
      <organization>Western Regional Medical Center</organization>
      <phone>623-207-3649</phone>
      <email>heather.barilla@ctca-hope.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
